3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Dermatologic
1
Conditions
Melanoma
4
Carcinoma, Basal Cell
4
Sarcoma, Kaposi
1
Carcinoma, Squamous Cell
1
Carcinoma, Merkel Cell
1
Carcinoma
1
Interventions
pembrolizumab
9
Nivolumab
4
Fluorouracil
4
Mohs Surgery
3
talimogene laherparepvec
2
atezolizumab
2
Therapeutics
2
Photochemotherapy
2
Petrolatum
2
Paclitaxel
2
Niacinamide
2
Aminolevulinic Acid
2
tozuleristide
1
smallpox and monkeypox vaccine modified vaccinia ankara-bavarian nordic
1
selinexor
1
regorafenib
1
peginterferon alfa-2b
1
peginterferon alfa-2a
1
osimertinib
1
nanocis
1
methyl 5-aminolevulinate
1
fludarabine
1
daromun
1
cobimetinib
1
cemiplimab
1
avelumab
1
aldesleukin
1
aflibercept
1
afamelanotide
1
Vitamin D
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Squamous Cell
×
daromun
×
Dermatologic
×
Clear all
NCT05329792
2023-10-06
IntriNSiC
Philogen S.p.A.
Phase 2
Unknown
70 enrolled